Back to search results

Phase I Study of [18F]FluorThanatrace (FTT) for Ovarian, Fallopian Tube, or Peritoneal Cancer

This study is testing a new radioactive drug called [18F]FluorThanatrace (FTT) with PET/CT scans. Researchers want to see how this drug moves through your body, how it's used, and how it leaves your system. They also want to see if it can help detect PARP-1 activity in ovarian, fallopian tube, or primary peritoneal cancer. You may be able to join if you are a woman aged 18 or older with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer, and have at least one tumor 1.0 cm or larger. The main goal is to track any side effects over three years. The study status is unclear, and it plans to enroll up to 35 participants.

Study design
This is an interventional study planning to enroll up to 35 women. It has two groups: a Biodistribution cohort (up to 4 patients) and a Dynamic cohort (up to 36 patients).
What's involved
Participants will undergo PET/CT imaging sessions after receiving the [18F]FluorThanatrace drug.
Compensation
Not stated in the trial record.
Follow-up
Adverse events will be measured for up to 3 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02637934

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Recruiting
PHASE1Ages 18+InterventionalTreatment
Abramson Cancer Center at Penn Medicine
~35 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:[18F]FluorThanatracePET/CT imaging sessions

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Adverse Events
Measured over 3 years

Conditions

Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Explore related trials

Fallopian Tube CarcinomaMalignant Ovarian NeoplasmPrimary Peritoneal Cancer

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Fiona Simpkins, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center at Penn Medicine

Who to contact

Fiona Simpkins, MD
[email protected]
855-216-0098
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants will be ≥ 18 years of age
History of known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer (may have primary or recurrent cancer at the time of study enrollment)
At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. CT, MRI, ultrasound, FDG PET/CT)

Exclusion

Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

What this trial measures

  • Number of Adverse Events3 years